MedTrace Logo

The Efficacy of Oral Probiotics on Neonatal Hyperbilirubinemia

NCT03876678 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2023-07-19

No results posted yet for this study

Summary

This trial will be carried out in two stages in the sick baby room of the Children's Hospital of China Medical University (CMUH). The first stage is: the enzyme active reaction kit (usually called API ZYM kit) was used to determine the β-glucuronidase activity of 9 strains of Lactobacillus and 4 strains of Bifidobacterium, screening out the probiotics that have the best inhibitory efficacy of intestinal β-glucuronidase activity; The second stage is: using the results of the first stage analysis, treating the newborns of jaundice by oral probiotics.

Conditions

  • Hyperbilirubinemia, Neonatal

Interventions

OTHER

Lactobacillus salivarius AP-32

Taking 1 probiotic capsule two times everyday for 7 days.

OTHER

Bifidobacterium animalis subspecies lactis CP-9

Taking 1 probiotic capsule two times everyday for 7 days.

OTHER

Placebo

Taking 1 placebo capsule two times everyday for 7 days.

Sponsors & Collaborators

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Hung-chih Lin · China Medical University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-24
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03876678 on ClinicalTrials.gov